Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Post-RYGB Hyperinsulinemic Hypoglycemia
NCT02685852Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Feb 2016
- Primary completion
- Jul 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of exenatide in hyperinsulinemic hypoglycemia (HH) (3 arms), sponsored by University of Minnesota. Primary endpoints: Glucose Area Under the Curve at 4 hours and Presence of Hypoglycemia. Started Feb 2016; status: completed.
02
Drugs
exenatide
03
Conditions
hyperinsulinemic hypoglycemia (HH)
Beyond the preview
Go deeper on NCT02685852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685852.